TITLE

SYSTEMIC TOXICITY OF CA-7 (FIBRINOLYTIC ENZYME FROM ASPERGILLUS ORYZAE) IN THE DOG

AUTHOR(S)
Roschlau, Walter H. E.
PUB. DATE
November 1966
SOURCE
Angiology;Nov1966, Vol. 17 Issue 11, p882
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The toxic effects of systemic thrombolytic doses of CA-7 (fibrinolytic enzyme from Aspergillus oryzae) in 36 dogs are summarized. The more important of these are transient hypocoagulability of the blood, transient hypotension, reversible hemoconcentration, reversible liver involvement and variable signs of extravasation at autopsy after sacrifice 24 to 72 hr later. Toxicity was related to the level of induced fibrinolytic activity. To have a predictable thrombolytic effect, CA-7 needed to be administered in doses that were large enough to depress inhibitors sufficiently. Excessive dosage, however, resulted in free proteolysis with often severe toxic manifestations. The subtoxic therapeutic dose range is shown, and the need for control of therapy is discussed.
ACCESSION #
16432542

 

Related Articles

  • THROMBOLYTIC THERAPY WITH LOCAL PERFUSIONS OF CA-7 (FIBRINOLYTIC ENZYME FROM ASPERGILLUS ORYZAE) IN THE DOG. Roschlau, Walter H.E.; Fisher, Albert M. // Angiology;Sep1966, Vol. 17 Issue 9, p670 

    The prompt lysis of intravenous and intra-arterial occluding thrombi with local perfusions of non-toxic of CA-7 (fibrinolytic enzyme from Aspergillus oryzae) in the dog is described. The action of blood inhibitors is demonstrated in comparative experiments with injections of CA-7 into thrombosed...

  • AN EXPERIMENTAL METHOD FOR QUANTITATIVE EVALUATION OF THROMBOLYSIS: EFFECT OF CA-7, A PROTEASE FROM ASPERGILLUS ORYZAE. Giering, John E.; Truant, Aldo P. // Angiology;Sep1966, Vol. 17 Issue 9, p661 

    A quantitative method is described which is based upon the insertion into the external jugular vein of a preformed, weighed blood clot formed and retracted around a special framework. The frame firmly supports and confines the clot in a fixed position within the vein without completely impeding...

  • Current Clinical Use of Reteplase for Thrombolysis: A Pharmacokinetic-Pharmacodynamic Perspective. Martin, U.; Kaufmann, B.; Neugebauer, G. // Clinical Pharmacokinetics;1999, Vol. 36 Issue 4, p265 

    Clinical evaluation of a new thrombolytic agent should start with a dose that provides adequate efficacy and has an acceptably low bleeding risk; this results in a narrow therapeutic window at the upper end of the dose-response curve. Angiographic patency of the infarct-related artery is still...

  • Are We Using Fibrinolytic Agents Often Enough? Marder, Victor J. // Annals of Internal Medicine;Jul80 Part 1, Vol. 93 Issue 1, p136 

    Editorial. Addresses the reluctance of physicians to use fibrinolytic therapy. Explanation for such attitude; Mechanism of action of fibrinolytic agents; Acceptance of heparin therapy.

  • Micromycetes in podzolic and bog-podzolic soils in the middle taiga subzone of northeastern European Russia. Khabibullina, F.; Kuznetsova, E.; Vaseneva, I. // Eurasian Soil Science;Oct2014, Vol. 47 Issue 10, p1027 

    The qualitative and quantitative characteristics of the mycobiota in podzolic and bog-podzolic soils were studied in the middle taiga subzone (the Republic of Komi). The complex of micromycetes was found to include 73 species of 18 genera from the Zygomycota and Ascomycota orders and from the...

  • Characterization of oxylipins and dioxygenase genes in the asexual fungus Aspergillus niger. Wadman, Mayken W.; de Vries, Ronald P.; Kalkhove, Stefanie I. C.; Veldink, Gerrit A.; Vliegenthart, Johannes F. G. // BMC Microbiology;2009, Vol. 9, Special section p1 

    Background: Aspergillus niger is an ascomycetous fungus that is known to reproduce through asexual spores, only. Interestingly, recent genome analysis of A. niger has revealed the presence of a full complement of functional genes related to sexual reproduction [1]. An example of such genes are...

  • THROMBOLYTIC THERAPY FOR PULMONARY EMBOLISM. Katchan, Brian M. // Canadian Journal of Surgery;Dec2000, Vol. 43 Issue 6, p411 

    Discusses the treatment of acute pulmonary embolism using thrombolytic therapy. Evidence on the effectiveness of thrombolytic agents to dissolve blood clot than heparin; Risk of major hemorrhage related to the use of thrombolytic agents; Acute right ventricular dysfunction as an indication for...

  • Clinical Trials of Thrombolytic Agents in myocardial Infarction. Simon, Toby L.; Ware, James H.; Stengle, James M. // Annals of Internal Medicine;Nov73, Vol. 79 Issue 5, p712 

    Presents information on several clinical trials of thrombolytic agents in myocardial infarction. Details on the German-Swiss trials; Description on the European Working Party trials; Overview on the Frankfurt short-term study; Result of the coronary care unit study.

  • Thrombolytic Therapy in Thrombosis: A National Institutes of Health Consensus Development Conference. Sherry, Sol; Bell, William R.; Duckert, F.H.; Fletcher, Anthony P.; Gurewich, Victor; Long, David M.; Marder, Victor J.; Roberts, Harold; Salzman, Edwin W.; Sasahara, Arthur; Verstraete, Marc // Annals of Internal Medicine;Jul80 Part 1, Vol. 93 Issue 1, p141 

    Editorial. Presents the consensus reached by a National Institutes of Health during a 1980 conference on thrombolytic therapy in thrombosis. Benefits for the use of thrombolytic therapy in acute deep-vein thrombosis and pulmonary embolism; Risks associated with the use of thrombolytic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics